Wire · opportunities
Safusidenib Demonstrates Durable Responses in IDH1-Mutant Glioma and Advances Into ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 6 October 2026 · Fusion42 review
Safusidenib, an oral selective IDH1 inhibitor, demonstrated durable antitumor activity in a phase 2 study of patients with grade 2 IDH1-mutant glioma, showing a 51.9% response rate and 79.1% progression-free survival at 36 months, leading to expanded clinical development plans including phase 3 trials for maintenance and earlier treatment settings.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You have a clear opening to develop targeted IDH1 mutant glioma therapies with safusidenib's proven durable control and tolerability; this widens patient access beyond current chemo and radiation and invites competition in maintenance and first-line treatment.
◆ Coverage
1 source · 6 Oct 2026
◆ Related on Wire
◆ Topics